MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 TrialA. Jo Chien, Laura J. Esserman, Anne M. Wallace et al.|Journal of Clinical Oncology|2020Cited by 113
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatmentShuying Liu, Debasish Tripathy|Breast Cancer Research|2023Cited by 24
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatmentShuying Liu, Debasish Tripathy|Research Square|2023Cited by 2